KTC
CAPR icon

Kistler-Tiffany Companies’s Capricor Therapeutics CAPR Stock Holding History

Kistler-Tiffany Companies’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-14
Closed -$1K – 602
2015
Q2 		$1K Buy
+14
New +$879 ﹤0.01% 574

Other funds holding CAPR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CFN
Cordasco Financial Network Naples, Florida $138M AUM 10.5% 1-Year Est. Return

Kistler-Tiffany Companies's CAPR Position: Q3 2015 in Review

Kistler-Tiffany Companies sold out of Capricor Therapeutics (CAPR) in Q3 2015, closing a stake of 14 shares — an estimated $1K sold.

Kistler-Tiffany Companies first reported a position in CAPR in Q2 2015 and held it in 1 quarter. The position peaked at $1K in Q2 2015. 15 funds tracked by Wall St. Rank hold CAPR as of Q3 2015.

  • Kistler-Tiffany Companies reported no remaining Capricor Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 14 Capricor Therapeutics shares in Q3 2015, an estimated $1K.
  • Kistler-Tiffany Companies first reported a position in Capricor Therapeutics in Q2 2015 and held it in 1 quarter.
  • Kistler-Tiffany Companies's Capricor Therapeutics position peaked at $1K in Q2 2015.
  • 15 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2015.

Based on Kistler-Tiffany Companies's 13F filing for Q3 2015, filed 6 Nov 2015.